Depreciation of Aligos Therapeutics, Inc. from 30 Sep 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Aligos Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 30 Sep 2019 to 31 Dec 2025.
  • Aligos Therapeutics, Inc. Depreciation for the quarter ending 31 Dec 2025 was $236,000, a 63% increase year-over-year.
  • Aligos Therapeutics, Inc. Depreciation for the twelve months ending 31 Dec 2025 was $930,000, a 9.4% decline year-over-year.
  • Aligos Therapeutics, Inc. annual Depreciation for 2025 was $930,000, a 9.4% decline from 2024.
  • Aligos Therapeutics, Inc. annual Depreciation for 2024 was $1,027,000, a 34% decline from 2023.
  • Aligos Therapeutics, Inc. annual Depreciation for 2023 was $1,559,000, a 32% decline from 2022.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Aligos Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $930,000 $236,000 +$91,000 +63% 01 Oct 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $839,000 $200,000 -$100,000 -33% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $939,000 $300,000 $0 0% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $939,000 $194,000 -$88,000 -31% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $1,027,000 $145,000 -$260,000 -64% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $1,287,000 $300,000 $0 0% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $1,287,000 $300,000 -$100,000 -25% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $1,387,000 $282,000 -$172,000 -38% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $1,559,000 $405,000 -$125,000 -24% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $1,684,000 $300,000 -$200,000 -40% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $1,884,000 $400,000 -$200,000 -33% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $2,084,000 $454,000 -$222,000 -33% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $2,306,000 $530,000 -$148,000 -22% 01 Oct 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $2,454,000 $500,000 -$300,000 -38% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $2,754,000 $600,000 -$200,000 -25% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $2,954,000 $676,000 -$65,000 -8.8% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $3,019,000 $678,000 -$338,000 -33% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $3,357,000 $800,000 +$92,000 +13% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $3,265,000 $800,000 +$120,000 +18% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $3,145,000 $741,000 +$410,000 +124% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $2,735,000 $1,016,000 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $708,000 +$321,000 +83% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $680,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $331,000 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q3 2019 $387,000 01 Jul 2019 30 Sep 2019 10-Q 25 Nov 2020 2020 Q3

Aligos Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $930,000 -$97,000 -9.4% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $1,027,000 -$532,000 -34% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $1,559,000 -$747,000 -32% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $2,306,000 -$713,000 -24% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
2021 $3,019,000 +$284,000 +10% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $2,735,000 +$1,339,000 +96% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $1,396,000 01 Jan 2019 31 Dec 2019 10-K 23 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.